Artiva Biotherapeutics, Inc. · NASDAQ:ARTV
Artiva Biotherapeutics — Corporate Update (May 2026)
33 slides from Artiva Biotherapeutics's corporate update, May 8, 2026
Slide 1: Artiva Biotherapeutics May 2026
Artiva Biotherapeutics May 2026 Exhibit 99.3
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking
Slide 3: Management Team with Deep Expertise in Cell & Gene Therapy and Autoimmune Disease
Management Team with Deep Expertise in Cell & Gene Therapy and Autoimmune Disease Fred Aslan Subhashis Banerjee Jennifer Bush Chris Horan Thad Huston Heather Raymon Nicholas Veomett CEO CMO COO CTOO SVP Research & Early Development VP, Corp Dev CFO Development Experience Across Multiple Notable Bloc
Slide 4: Opportunity Summary
Opportunity Summary Deep B-cell depletion – potent mechanism vis-à-vis other novel approaches Artiva Biotherapeutics 1 6 2 Strategic interest across modalities (auto-CAR-T, TCE, in vivo, allo) 3 Refractory RA – approx. $5B* being spent on patients unlikely to respond after failed 2+ b/tsDMARDs 4 All
Slide 5: Consistent Activity Observed Across Indications
Consistent Activity Observed Across Indications N=14 aNHL, N=24 r/rHL, Over 70 Autoimmunity Patients Initiated Treatment as of end of April 2026 Artiva Biotherapeutics mDoR (mo) ≥19.4 (N.R.) 23.1 No discontinuations due to AEs, no patient started a new b/tsDMARD CRR % imab Auto-CAR-T benchmark* aNHL
Slide 6: B-Cell Depletion and "Reset" Hypothesis
B-Cell Depletion and “Reset” Hypothesis Artiva Biotherapeutics Autoantibody production / tissue damage Cytokine secretion / inflammation Antigen presentation / T cell amplification Role of B cells in autoimmune disease: 1 2 3 “Reset” with naive / transitional B cell phenotype Rituximab “Dimming” Dur
Slide 7: AlloNK: CD16 drives ADCC against B cells
Supportive CY/FLU conditioning CD8/CD4 rejection NK rejection (missing self) HLA ab (ADCP- macrophage, ADCC- NK, neutrophils) AlloNK: CD16 is a strong cell activating receptor, driving ADCC against B cells AlloNK (NK cell) Pathogenic B-cell CD16 B-cell Antigen X 1 2 3 Rejection D1 D2 D3 D6 D20 CY/FL
Slide 8: AlloNK + RTX Showed Consistent Complete B-Cell Depletion in Autoimmune Diseases
AlloNK + RTX Showed Consistent Complete B-Cell Depletion in Autoimmune Diseases Opportunity to see B-cell reconstitution within 6 to 12 months following treatment B-cell Reconstitution in Patients Treated with AlloNK + RTX Consistent with Auto-CAR T Academic Study Uniform and consistent B-cell deple
Slide 9: AlloNK + RTX Showed Complete B-Cell Depletion Using High Sensitivity Assay
AlloNK + RTX Showed Complete B-Cell Depletion Using High Sensitivity Assay Note: No head-to-head trial has been conducted evaluating AlloNK against other data included herein. Differences exist between clinical trial design, patient populations and the product candidates/products themselves, and cau
Slide 10: Incomplete Depletion Likely Leads to Relapse
Incomplete Depletion Likely Leads to Relapse Blinatumomab (CD19 TCE) B-cell depletion in 6 patients with RA1 Bucci et al Nat Med 2024(2) Grieshaber-Bouyer et al 2026 Accelerating Bio-Innovation (ABI) Conference 9 of 15 relapsed by 3 mos 13 of 15 relapsed by 6 mos 2 Artiva Biotherapeutics
Slide 11: The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs
The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs % of RA patients achieving ACR50 Response 1st 2nd TNF 3rd and later b/tsDMARD line (1) SELECT-COMPARE. Fleischmann et al 2019 DOI 10.1002/art.41032; wk12(2) Humira USPI, Study RA-III, 6mo(3) SELECT-BEYOND. Genovese et al 2018
Slide 12: ~$5B Spent on US RA Patients Who Failed 2+ b/tsDMARDs
~$5B Spent on US RA Patients Who Failed 2+ b/tsDMARDs Artiva Biotherapeutics 820k treated w/ csDMARD (e.g. MTX) 1.5M Total Diagnosed U.S. Prevalence [1] Mild: 45%[1] Moderate/Severe: 55% [1] 150-200k Failed 2+ b/tsDMARDs [2] US RA market: ~$20B/yr[3-6] ~575k treated with b/tsDMARDs [2] ~$5B/yr (25%*
Slide 13: AlloNK+RTX Initial Clinical Data in RA: Patient Demographics
AlloNK+RTX Initial Clinical Data in RA: Patient Demographics Artiva Biotherapeutics Mean (range) Demographics Age (yrs) 52.5 (31-76) Female (%) 100% Disease Duration (yrs) 14.8 (1.6-41) Disease Activity CDAI 50.7 (24.9-75.6) DAS28-ESR 7.3 (5.5-8.9) * n=6 from IIT (NCT06581562); n=15 from company-spo
Slide 14: CDAI & DAS28-ESR Reduction Observed
CDAI & DAS28-ESR Reduction Observed at 3 or 6 Months Artiva Biotherapeutics Subject RA-2 RA-5 RA-6 RA-3 RA-1 RA-4 RA-11 RA-10* RA-13 RA-8* RA-12 RA-7 RA-9 RA-19 RA-20 RA-21 RA-17 RA-15* RA-18* RA-14 RA-16 Change in CDAI Change in DAS28-ESR MCII* (≥ 12 for CDAI; ≥ 1.2 for DAS28) Baseline CDAI 36 34 5
Slide 15: CDAI & DAS28 Change from Baseline
CDAI & DAS28 Change from Baseline Artiva Biotherapeutics CDAI (mean 50.7 baseline) Month N= 21 13 Month DAS28-ESR (mean 7.3 baseline) * Minimal Clinically Important Improvement ϕ CRP collected in basket study only POOLED INITIAL DATA AS OF 03APR2026; Month 3 = 12wks; Month 6 = 22 or 24 wks [1] Subj
Slide 16: ACR50 Scoring Using Currently Available ACR Components as Proxy
ACR50 Scoring Using Currently Available ACR Components as Proxy Artiva Biotherapeutics PhGA PtGA SJC TJC HAQ-DI ESR or CRP Pain 3 of 5 ACR50 mACR50 ACR Components 2 of 3 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Slide 17: ACR Component Scores
ACR Component Scores Artiva Biotherapeutics Swollen Joints (SJC) Month Clinical response (>50% reduction) POOLED INITIAL DATA AS OF 03APR2026; Month 3 = 12wks; Month 6 = 22 or 24 wks N= 21 13 Tender Joints (TJC) Month N= 21 13 Required for ACR50 Response: ≥ 50% improvement in both SJC and TJC Newer
Slide 18: High Initial ACR Response Rate Observed
High Initial ACR Response Rate Observed at 6 Months Artiva Biotherapeutics mACR50 calculated only for the IIT, where HAQ-DI and Pain were not collected: TJC&SJC >50% and 2 other components >50% POOLED INITIAL DATA AS OF 03APR2026; Month 6 = 22 or 24 wks; Last Visit Carried Forward for missing data 8
Slide 19: High ACR Response Rate Observed in Refractory RA Patients at 6 Months
High ACR Response Rate Observed in Refractory RA Patients at 6 Months 19 Artiva Biotherapeutics ACR Responses Among RA Patients in Company-Sponsored Basket Study INITIAL DATA AS OF 03APR2026; Month 6 = 22 wks; Last Visit Carried Forward for missing data Deep responses, supporting TPP of ≥50% ACR50 a
Slide 20: "Swimmer's plot" for RA patients
“Swimmer’s plot” for RA patients Artiva Biotherapeutics AlloNK treatment cycle On-study; no steroids beyond “soft rescue”; no new b/tsDMARDs Loss of response* or study discontinuation û ϕ Noted at 3mo only if subject achieved ACR50 at 6mo (Subject RA-2 had ACR50 at 3mo but not 6mo; all others mainta
Slide 21: Tolerability Profile of AlloNK + RTX Compared to Auto CAR-T and T-Cell Engagers
Tolerability Profile of AlloNK + RTX Observed Compared Favorably to Autologous CAR-T and BCMA Targeted T-Cell Engagers AlloNK + ritux Auto CAR-T Schett / CASTLE1 T-Cell Engager teclistamab2 No. of Patients 55 24 10 CRS (any/Gr 3+) - / - 75% / - 80% / - Tocilizumab for CRS - 58% 80% Infections (any/G
Slide 22: Experience in First Autoimmune Patients Treated with AlloNK + RTX
Experience in First 55 Autoimmune Patients Treated with AlloNK + RTX Hospitalization Rates Consistent with mAb Alone Showing Ability to Manage Patients as Outpatient Pooled initial data as 03Apr, 2026 data cutoff for CY/FLU + AlloNK + rituximab from ongoing autoimmune clinical trials: Phase 2a baske
Slide 23: Neutrophil Counts Returned to Normal in Most RA Subjects
Neutrophil Counts Returned to Normal by Day 28 in Most RA Subjects Artiva Biotherapeutics Data cut as of April 3, 2026 Absolute Neutrophil Counts in N=30 RA subjects from AB-101-05 and IRIS-RD-01 studies
Slide 24: Cell Therapy-like Activity with Biologics-like Ease-of-Use
Illustrative Rethinking of Cell Therapy-like Activity with Biologics-like Ease-of-Use Artiva Biotherapeutics AlloNK AlloNK AlloNK AlloNK AlloNK Potential for long-term control on AlloNK – off other chronic meds 18-24+ months 30d “acute” Phase Off immunomodulatory drugs Low doses of CY/FLU 4 3 Scalab
Slide 25: Registrational Strategy
Registrational Strategy Single registrational RCT; N = ~150 RA pts with inadequate response to 2+ b/tsDMARDs Randomized 2:1 to AlloNK + RTX vs. RTX-only Primary efficacy end point: ACR50 at 6 months AlloNK dosing: 4B cells x 2 doses (Days 6 and 20) RTX-only non-responders may cross-over into AlloNK
Slide 26: Program Commercial Objectives
Artiva Biotherapeutics To be the first FDA-approved deep B-cell depleting therapy for refractory RA patients who have failed 2+ b/tsDMARDs To be a one-time treatment (“reset”) lasting more than 18 months with several patients still benefiting 3 years later; patients off other immunomodulatory drugs
Slide 27: Illustrative Market Reach in US alone
Illustrative Market Reach in US alone Reimbursement framework expected to be in line with other IV therapies Artiva Biotherapeutics 250 clinics 1-2 patients per month 50 clinics in RCT in US …out of >2,000 rheum community clinics with infusion chairs [1,2] …where top HCPs see estimated 20-30 2+b/tsD
Slide 28: Clinical Responses Observed in SjD
Clinical Responses Observed in SjD Artiva Biotherapeutics N= 11 7 ESSPRI (change) (Mean +/- SEM) N= 11 7 ESSDAI (change) (Mean +/- SEM) SSF at 6mo (change) (Mean +/- SEM) Months Months INITIAL DATA AS OF 03APR2026; Month 3 = 12wks; Month 6 = 22 or 24 wks Mean 13.1 baseline Mean 8.0 baseline Mean 0.6
Slide 29: Clinical Responses Observed in SjD
Clinical Responses Observed in SjD Artiva Biotherapeutics INITIAL DATA AS OF 03APR2026; No head-to-head trial has been conducted evaluating AlloNK against other data included herein. Differences exist between clinical trial design, patient populations and the product candidates/products themselves,
Slide 30: Clinical Responses Observed in Systemic Sclerosis (SSc)
Clinical Responses Observed in Systemic Sclerosis (SSc) Artiva Biotherapeutics * rCRISS25: ≥25% probability (score ≥0.25) that a patient has improved overall. rCRISS50: ≥50% probability (score ≥0.50) of overall improvement, a stricter threshold. Initial data as of 03Apr2026 mRSS (change) (Mean +/- S
Slide 31: Expected Data and Trial Maturation in RA
Expected Data and Trial Maturation in RA H2’26 Artiva Biotherapeutics H1’27 H2’27 H1’28 H2’28 30+ total pts 15+ pts w/ ACR50@6m RA open-label update: 50+ total pts 40+ pts w/ ACR50@6m 20+ pts w/ 12-18+ mos f/u 50+ total pts w/ 18-36 mos f/u RCT read-out RA RCT Enrollment complete Trial initiation Pl
Slide 32: Road Map to Becoming Potential First-in-Class
Road Map to Becoming Potential First-in-Class Artiva Biotherapeutics Deep B-cell depletion MoA (low sensitivity + high sensitivity B-cell assay, B-cell reconstitution) Initial safety profile consistent with desired TPP in community (rheumatologists can “own”) Efficacy/initial durability signal >>> S
Slide 33: Opportunity Summary
Opportunity Summary Deep B cell depletion - potent mechanism vis-à-vis other novel approaches Artiva Biotherapeutics 1 6 2 Strategic interest across modalities (auto-CAR-T, TCE, in vivo, allo) 3 Refractory RA – approx. $5B* being spent on patients unlikely to respond after failed 2+ b/tsDMARDs 4 All